Medicines are distributed through a complex supply chain which may be disrupted anywhere from manufacturing to dispensing. Factors that contribute to unanticipated shortages of medicines include manufacturing causes, logistical failures and unexpected or unpredictable disease outbreaks. Additionally, in the postmarketing environment unexpected safety signals may require recall of batches, with a consequential scarcity of remaining supplies at short notice. early identification of potential stock shortages and early engagement with the Therapeutic Goods Administration will facilitate a coordinated response in managing interruptions or changes to patient care. Pharmaceutical companies and the Therapeutic Goods Administration will endeavour to provide the right product or appropriate alternative therapies to ensure that patient care is not appreciably diminished.
introduction
The National Medicines Policy has four central objectives focused on delivering medication and related health services that meet best possible health and economic objectives. 1 Ensuring timely access to medicines encompasses the entire journey from molecule to patient. It includes research and development programs, a rigorous regulatory system for assessing quality, safety and efficacy, 2 and a government subsidy scheme. 3 There have been a few notable unexpected shortages in the supply of prescription medicines in Australia. While these events are generally few and far between, when they occur they generate concern and incredulity at the vulnerability of the medicines supply chain.
The supply chain
Medicines are distributed through a complex supply chain starting with formulation and manufacturing. 
Manufacturing
The causes of production failures can be diverse. Changes in manufacturing processes can cause challenges in meeting regulatory requirements. This is a particular problem with biological products where apparently minor manufacturing changes may create unexpected variations in the quality of the final product.
Many manufacturers rely on third parties for raw materials.
If supplies are not received or raw materials fail to meet the required specifications this will disrupt production schedules. 
Maintaining supply
The industry's predictive mechanisms do not generally account for unforeseen surges in demand, or for unintended breakdowns in supply. However, extended shelf lives, careful adherence to storage recommendations and maintenance of a reserve stock may compensate for short-lived, unexpected incidents.
There is a fine balance between the holding of safety stock to cover potential shortages and keeping inventory as low as is practicable to avoid wastage caused by stock expiring. As soon as the likelihood of a shortage is confirmed, companies endeavour to establish its probable duration. This will enable the company to determine if safety stocks are sufficient or whether the product can be supplemented from alternative sources.
Vaccines have their own specific challenges and continuation of supply is a constant concern due to the complexity of the production process. Demand is also variable, for example with the uptake of seasonal vaccines. This requires careful stock management and mechanisms for rapid redirection of international supplies.
Sponsors may implement systems whereby stock is assigned and packaged for particular countries at the last minute to enable redirection of supplies at short notice to areas of need.
This is a common means of managing the drugs used in clinical trials where recruitment rates may be uncertain.
Cooperation with regulators
When a product is predicted to be out of stock for only Substitute treatment regimens with alternative products were established which prioritised patients according to clinical need. 5 In 2009 supplies of imiglucerase for the treatment of Gaucher's disease, and agalsidase-beta for the treatment of Fabry's disease were significantly depleted due to manufacturing problems.
This resulted in a worldwide shortage of these products. The coordinated global and local response recommended rationing the use of remaining product to extend existing supplies for as long as possible. 6 The manufacturer of these products continues to work with government and patient support organisations for the ongoing management of supply. 6
Conclusion
Medicines manufacturers and suppliers try to prevent shortages of products wherever possible. To achieve this effectively they rely on accurate forecasting, maintenance of appropriate levels of safety-stock and identification of backup supply routes. The TGA has a number of powers under the Therapeutic Goods Act, to permit supply of unapproved products in critical situations. 4 Early identification of potential stock shortages and early engagement with the TGA enables a coordinated response to assist in managing interruptions or changes to patient care.
Both the companies and the TGA will endeavour to provide a product, or appropriate alternative therapies, to ensure that patient care is not appreciably diminished. 
